BMI1 and melanoma: miR-200c has been proposed to prevent the establishment of drug resistance in melanoma by targeting Bmi-1, Zeb2, Tubb3, ABCG5, and MDR1, transcriptional repressors that belong to a complex signaling network involved in the epithelial to mesenchymal transition (EMT).